Thousands of men in England are set to benefit from a new NICE-approved prostate cancer treatment that offers life-extending results with fewer side effects. In this blog, Dr Richard Dune explores the approval of darolutamide combined with androgen deprivation therapy, a milestone that halves the risk of death for men with advanced prostate cancer who cannot tolerate chemotherapy. He examines what this means for patients, professionals, and the wider health system from improving equity and access to embedding new NICE guidance into governance, compliance, and workforce training across the NHS.